MK-3118

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2017
01220102017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
SCY-078 (MK-3118) is a novel, semisynthetic derivative of enfumafungin and represents the first compound of the triterpene class… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2017
2017
SCY-078 (formerly MK-3118) is a novel orally active inhibitor of fungal β-(1,3)-glucan synthase (GS). SCY-078 is a derivative of… (More)
Is this relevant?
2015
2015
Echinocandins inhibit the synthesis of β-1,3-D-glucan in Candida and are the first-line therapy in numerous clinical settings… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2015
2015
The limited armamentarium of active and oral antifungal drugs against emerging non-Aspergillus molds is of particular concern… (More)
  • table 1
Is this relevant?
2014
2014
MK-3118 is as an orally active new antifungal in the early stage of clinical development that inhibits the biosynthesis of β-(1,3… (More)
Is this relevant?
2013
2013
OBJECTIVES To evaluate the activity of the orally bioavailable enfumafungin derivative MK-3118 and comparator antifungal agents… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2013
2013
MK-3118, a glucan synthase inhibitor derived from enfumafungin, and comparator agents were tested against 71 Aspergillus spp… (More)
Is this relevant?
Review
2011
Review
2011
INTRODUCTION New classes of synthetic and semi-synthetic β-glucan inhibitors have recently emerged, providing analogs that, in… (More)
Is this relevant?
2010
2010
The 50th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held in Boston, included topics… (More)
Is this relevant?